top of page

Toltrazuril For Horses

Updated: May 8, 2023

Toltrazuril is a drug that has gained popularity in the treatment of Equine Protozoal Myeloencephalitis (EPM) in horses. EPM is a neurological disease caused by a parasite called Sarcocystis neurona. It affects the central nervous system of the horse and can lead to a range of symptoms, including muscle wasting, ataxia, and weakness.

Toltrazuril is an anticoccidial drug that works by inhibiting the development of the parasite in the horse's body. It has been shown to be effective in treating EPM in horses, particularly when used in conjunction with other therapies such as anti-inflammatory medications and physical therapy.

One of the benefits of toltrazuril is that it is an oral medication, which makes it easy to administer to horses. It is typically given once a day for a period of two weeks, and it can be repeated as needed if the horse's symptoms persist.

Studies have shown that toltrazuril is effective in treating EPM in horses, with a success rate of around 60-80%. However, it is important to note that not all horses will respond to the treatment, and some may require additional therapies or a different course of treatment. While toltrazuril is generally considered safe for horses, there are some potential side effects to be aware of. These can include gastrointestinal upset, lethargy, and a decreased appetite. In rare cases, more serious side effects such as liver damage or allergic reactions can occur. It is important to work closely with a veterinarian when treating a horse with toltrazuril for EPM. The vet can monitor the horse's progress and adjust the treatment plan as needed. They can also provide guidance on how to manage any side effects that may occur.

In summary, toltrazuril is an effective treatment option for EPM in horses. It is a safe and easy-to-administer medication, but it is important to work with a veterinarian to ensure that the horse is receiving the appropriate treatment and care.

CLICK HERE to order Toltrazuril Products

62 views0 comments


bottom of page